Here's What Analysts Think About Telix Pharmaceuticals (TLX) [Yahoo! Finance]
Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Company Research
Source: Yahoo! Finance
Cowen lowered its price target on Telix Pharmaceuticals Limited (NASDAQ:TLX) from AUD 35 to AUD 25 but kept its Buy rating on the stock. Earlier, on December 14, RBC Capital also initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX), assigning the stock a Sector Perform rating and setting the price target at AUD 17. The firm noted that Telix Pharmaceuticals Limited (NASDAQ:TLX) is a radiopharmaceutical company that has successfully commercialized two diagnostic products for prostate cancer. The company has significant potential to expand into other indications. The research firm highlighted the company's extensive portfolio and pipeline of assets in urology, neurology, musculoskeletal, and hematologic oncology, which the company is making efforts to commercialize. While RBC Capital acknowledges these opportunities, it expects Telix Pharmaceuticals Limited's (NASDAQ:TLX) earnings and free cash flow to remain largely flat between fiscal years 2025 and 2027 as the compan
Show less
Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLX alerts
High impacting Telix Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TLX
News
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis StudyPR Newswire
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis StudyGlobeNewswire
- Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLXGlobeNewswire
- TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today’s Lead Plaintiff Deadline in Securities Class ActionGlobeNewswire
- TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their RightsGlobeNewswire
TLX
Sec Filings
- 1/12/26 - Form 6-K
- 12/22/25 - Form 6-K
- 12/17/25 - Form 6-K
- TLX's page on the SEC website